Table 2 General demographic and clinics characteristics in Metabolic Syndrome

Number (%)

44

43

Age (years)

55.20 ± 12.49

56.20 ± 12.49

Males n (%)

28 (63.60)

27 (62.79)

Years of evolution

1.58 ± 2.06

1.58 ± 2.06

Smokers n (%)

9 (20.50)

9 (20.93)

Ischemic heart disease n (%)

2 (4.50)

2 (4.65)

Cerebrovascular disease n (%)

0 (0.00)

0 (0.00)

BMI (kg/m²)

31.08 ± 3.52

30.82 ± 4.05

-0.26

-0.61

to

0.05

0.094

Waist circumference (cm)

104.75 ± 9.76

104.79 ± 8.98

0.04

-1.34

to

1.52

0.896

Total Cholesterol (mg/dL)

218.95 ± 44.15

208.51 ± 41.26

-10.44

-21.60

to

0.06

0.051

Tryglicerides (mg/dL)

167.68 ± 53.07

151.02 ± 83.70

-16.66

-38.47

to

7.54

0.182

LDL cholesterol (mg/dL)

140.25 ± 39.67

130.56 ± 35.94

-9.69

-19.85

to

0.04

0.051

HDL cholesterol (mg/dL)

45.18 ± 10.96

47.38 ± 11.42

2.20

0.16

to

3.65

0.033

Serum glucose (mg/dL)

92.57 ± 11.78

88.91 ± 12.52

-3.66

-7.02

to

-0.47

0.026

HbA1c

5.59 ± 0.66

5.67 ± 0.32

0.08

-0.11

to

0.30

0.367

Serum creatinine, (mg/dL)

0.89 ± 0.16

0.90 ± 0.19

0.01

-0.03

to

0.05

0.575

hs-c-reactive (mg/dL)

0.26 ± 0.21

0.27 ± 0.25

0.01

-0.04

to

0.05

0.687

Fibrinogen (mg/dL)

327.05 ± 59.07

345.16 ± 66.64

18.11

6.87

to

44.21

0.009

HOMA-IR

2.96 ± 1.82

2.22 ± 1.33

-0.74

-1.35

to

-0.27

0.004

Office SBP (mm Hg)

142.43 ± 12.46

134.95 ± 15.52

-7.48

-11.35

to

-2.18

0.005

Office DBP (mm Hg)

88.63 ± 9.61

84.92 ± 10.26

-3.71

-6.32

to

-0.26

0.034

Office PP, mm Hg

54.23 ± 11.35

50.77 ± 12.78

-3.46

-6.96

to

0.73

0.109

Office HR

74.23 ± 12.23

72.44 ± 11.66

-1.79

-3.78

to

0.94

0.232

Mean Antihypertensive Drugs

0.82 ± 1.04

1.34 ± 1.20

0.52

0.21

to

0.83

0.002

Antihypertensive Drugs, n (%)

21 (47.70)

31 (72.10)

24.40

-44

to

40

0.001

Mean Lipid lowering drugs

0.30 ± 0.46

0.43 ± 0.55

0.13

0.03

to

0.24

0.013

Lipid lowering drugs, n (%)

13 (29.50)

19 (44.20)

14.70

-3.5

to

450.0

0.031